Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 12, 2013, Pages 2631-2638

  Dabaja, Bouthaina S ^a   Phan, Jack ^a   Mawlawi, Osama ^a   Medeiros, L Jeffrey ^a   Etzel, Carol ^a   Liang, Fu Wen ^a   Podoloff, Donald ^a   Oki, Yasuhiro ^a   Hagemeister, Fredrick B ^a   Chuang, Hubert ^a   Fayad, Luis E ^a   Westin, Jason Robert ^a   Shihadeh, Ferial ^a   Allen, Pamela K ^a   Wogan, Christine F ^a   Rodriguez, Maria A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapeutic approaches; Clinical results; Lymphoma and Hodgkin disease

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MESNA; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883854373     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.784967     Document Type: Article

References (30)

1. Alizadeh AA, Eisen MB, Davis RE, et al . Distinct types of diff use large B-cell lymphoma identifi ed by gene expression profi ling . Nature 2000 ; 403 : 503-511 .
2. Fisher RI, Shah P . Current trends in large cell lymphoma . Leukemia 2003 ; 17 : 1948-1960 .
3. Miller TP, Dahlberg S, Cassady JR, et al . Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin' s lymphoma . N Engl J Med 1998 ; 339 : 21-26 .
4. Feugier P, V an Hoof A, S ebban C, et a l. L ong-term results of the R-CHOP study in the treatment of elderly patients with diff use large B-cell lymphoma: a study by the Groupe d' Etude des Lymphomes de l' Adulte . J Clin Oncol 2005; 23: 4117-4126.
5. Ballonoff A, Rusthoven KE, Schwer A, et al . Outcomes and eff ect of radiotherapy in patients with stage I or II diff use large B-cell lymphoma: a surveillance, epidemiology, and end results analysis . Int J Radiat Oncol Biol Phys 2008; 72: 1465-1471.
6. A predictive model for aggressive non-Hodgkin' s lymphoma . The International Non-Hodgkin' s Lymphoma Prognostic Factors Project . N Engl J Med 1993; 329: 987-994.
7. Lenz G, Wright G, Dave SS, et al . Stromal gene signatures in large-B-cell lymphomas . N Engl J Med 2008; 359: 2313-2323.
8. Meyer PN, Fu K, Greiner TC, et al . Immunohistochemical methods for predicting cell of origin and survival in patients with diff use large B-cell lymphoma treated with rituximab . J Clin Oncol 2011; 29: 200-207.
9. Juweid ME, Stroobants S, Hoekstra OS, et al . Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma . J Clin Oncol 2007 ; 25 : 571-578 .
10. Juweid M E, C heson B D. R ole of positron emission tomography in lymphoma . J Clin Oncol 2005 ; 23 : 4577-4580 .
11. Bangerter M, K otzerke J, G riesshammer M, et a l. P ositron emission tomography with 18-fl uorodeoxyglucose in the staging and follow-up of lymphoma in the chest . Acta Oncol 1999; 38: 799-804.
12. Spaepen K, Stroobants S, Dupont P, et al . Prognostic value of positron emission tomography (PET) with fl uorine-18 fl uorodeoxyglucose ([18F] FDG) after fi rst-line chemotherapy in non-Hodgkin' s lymphoma: is [18F]FDG) after fi rst-line chemotherapy in non-Hodgkin' s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods J Clin Oncol 2001 ; 19 : 414-419 .
13. Juweid ME, Wiseman GA, Vose JM, et al . Response assessment of aggressive non-Hodgkin' s lymphoma by integrated International Workshop Criteria and fl uorine-18-fl uorodeoxyglucose positron emission tomography . J Clin Oncol 2005 ; 23 : 4652-4661 .
14. Cronin CG, Swords R, Truong MT, et al . Clinical utility of PET/CT in lymphoma . AJR Am J Roentgenol 2010; 194: W91-W103.
15. Dupuis J, Itti E, Rahmouni A, et al . Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diff use large B-cell lymphoma: integrating 18fl uorodeoxyglucose positron emission tomography to the International Workshop Criteria . Ann Oncol 2009; 20: 503-507.
16. Phan J, Mazloom A, Medeiros LJ, et al . Benefi t of consolidative radiation therapy in patients with diff use large B-cell lymphoma treated with R-CHOP chemotherapy . J Clin Oncol 2010 ; 28 : 4170-4176 .
17. Carbone PP, Kaplan HS, Musshoff K, et al . Report of the Committee on Hodgkin' s Disease Staging Classifi cation . Cancer Res 1971 ; 31 : 1860-1861 .
18. Miller T P, G rogan T M, D ahlberg S, et a l. P rognostic signifi cance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin' s lymphomas: a prospective Southwest Oncology Group trial . Blood 1994 ; 83 : 1460-1466 .
19. Noy A, S choder H, G onen M, et a l. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diff use large B-cell lymphoma (DLBCL) . Ann Oncol 2009 ; 20 : 508-512 .
20. JM, C omans E F, v an Lingen A, et a l. F DG PET in lymphoma: the need for standardization of interpretation . An observer variation study. Nucl Med Commun 2007 ; 28 : 798-803 .
21. Terasawa T, Nihashi T, Hotta T, et al . 18F-FDG PET for posttherapy assessment of Hodgkin' s disease and aggressive Non-Hodgkin' s lymphoma: a systematic review. J Nucl Med 2008; 49: 13-21.
22. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al . 18F-fl uoro-deoxyglucose positron emission tomography for posttreatment evaluation of malignant lymphoma: a systematic review . Haematologica 2006; 91: 522-529.
23. Cheson BD, Pfi stner B, Juweid ME, et al . Revised response criteria for malignant lymphoma . J Clin Oncol 2007 ; 25 : 579-586 .
24. Meignan M, Gallamini A, Haioun C . Report on the First International Workshop on Interim-PET-Scan in Lymphoma . Leuk Lymphoma 2009; 50: 1257-1260.
25. Barrington SF, Qian W, Somer EJ, et al . Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma . Eur J Nucl Med Mol Imaging 2010 ; 37 : 1824-1833 .
26. Safar V, Dupuis J, Itti E, et al . Interim [18F]fl uorodeoxyglucose positron emission tomography scan in diff use large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab . J Clin Oncol 2012 ; 30 : 184-190 .
27. Haioun C, Itti E, Rahmouni A, et al. [18F]fl uoro-2-deoxy-Dglucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome . Blood 2005 ; 106 : 1376-1381 .
28. Morton LM, Wang SS, Devesa SS, et al . Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 . Blood 2006; 107: 265-276.
29. Seyfarth B, Josting A, Dreyling M, et al . Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diff use large cell lymphoma and Hodgkin disease . Br J Haematol 2006; 133: 3-18.
30. Engert A, Haverkamp H, Kobe C, et al . Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin' s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial . Lancet 2012 ; 379 : 1791-1799 .